medigraphic.com
ISSN 0210-5187 (Digital)

2003, Número 5

<< Anterior Siguiente >>

Med Cutan Iber Lat Am 2003; 31 (5)


Tratamiento tópico y cumplimentación en psoriasis vulgaris.

Eficacia clínica de una combinación singular de calcipotriol y dipropinato de betametasona.

Pautas de tratamiento de los brotes en psriasis vulgaris y pauta de mantenimiento.

Idioma: Español
Referencias bibliográficas: 48
Paginas: 323-336
Archivo PDF: 347.68 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB Jr. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J. 2003;9:2.

  2. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med. 1999;107:595-605.

  3. Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc. 2001;76:943-9.

  4. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment.J Am Acad Dermatol. 2000 ;42:796-802.

  5. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol. 2001;45:487-98

  6. Tremblay JF, Bissonnette R. Topical agents for the treatment of psoriasis, past, present and future. J Cutan Med Surg. 2002;6(Suppl 3):8-11.

  7. Thami GP, Sarkar R. Coal tar: past, present and future. Clin Exp Dermatol. 2002;27:99-103.

  8. Silverman A, Menter A, Hairston JL. Tars and anthralins. Dermatol Clin. 1995;13:817-33.

  9. Trozak DJ. Topical corticosteroid therapy in psoriasis vulgaris: update and new strategies.Cutis. 1999; 64:315-8.

  10. Lebwohl M. Psoriasis.Lancet. 2003;361:1197-204.

  11. Griffiths WAD, Wilkinsonn JD. Topical therapy. En Texbook of Dermatology. 6ª Ed. 1998. Ed. Champion RH, Burton JL, Burns DA, Breathnach SM, Blackwell Science. Oxford. pag. 3552.

  12. Anigbogu AN, Maibach HI. Topical Corticosteroid Therapy. En “Drug Therapy in Dermatology. 2000. Ed. Millikan LE. Marcel Dekker Inc. New York. Pag. 1-29.

  13. Lee NP, Arriola ER. Topical corticosteroids: back to basics.West J Med. 1999;171:351-3.

  14. Valencia IC, Kerdel FA. Topical Glucocorticoids. En Fitzpatrick´s Dermatology in General Medicine, 6ª ed. 2003. Ed. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI.Mc Graw-Hill. New York, pag 2324-7.

  15. Miller JJ, Roling D, Margolis D, Guzzo C. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol. 1999;41:546-9.

  16. Lagos BR, Maibach HI. Frequency of application of topical corticosteroids: an overview. Br J Dermatol. 1998;139:763-6.

  17. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol. 2002;3:47-58.

  18. Lebwohl M. Vitamin D and topical therapy. Cutis. 2002;70:5-8.

  19. Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol. 2001;2:95-120.

  20. Bikle DD. Vitamin D: a calciotropic hormone regulating calcium-induced keratinocyte differentiation. J Am Acad Dermatol. 1997;37:S42-52.

  21. Ashcroft DM, Po AL, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ. 2000;320:963-7.

  22. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol. 2002;146:351-64.

  23. Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol. 2000;43:S31-5.

  24. Guenther LC. Optimizing treatment with topical tazarotene. Am J Clin Dermatol. 2003;4:197-202.

  25. Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, Lew-Kaya DA, Sefton J, Gibson JR, Walker PS.Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48:760-7.

  26. Endzweig-Gribetz CH, Brady C, Lynde C, Sibbald D, Lebwohl M. Drug interactions in psoriasis: the pros and cons of combining topical psoriasis therapies. J Cutan Med Surg. 2002;6(Suppl 3):12-6.

  27. Koehler AM, Maibach HI. Electronic monitoring in medication adherence measurement. Implications for dermatology. Am J Clin Dermatol 2001;2:7-12.

  28. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-4.

  29. Weiss SC, Bergstrom KG, Weiss SA, Kimball AB. Quality of life considerations in psoriasis treatment. Dermatol Nurs 2000;120: 123-7.

  30. Richards HL, Fortune DG, O’Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41:581-3.

  31. Zaghloul SS, Goodfield MJD. Compliance in psoriasis:patients´self reporting and factors affecting medication adherence. Br J Dermatol 147 (Suppl 62): 43-4.

  32. van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology. 1998;197:31-6.

  33. Cullen SI. Long term effectiveness and safety of topical calcipotriene for psoriasis. South Med J 1996; 89:1053-6.

  34. Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, Kaufmann R, Rogers S, Van de Kerkhof PCM, Hanssen LI, Tegner E, Burg G, Talbot D, Chu A and the Study Group. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48:48-54.

  35. Traulsen J. Bioavailability of betamethasone dipropionate when combined with calcipotriol. J Eur Acad Dermatol Venereol 2001; 15 (Supp.2):24-52.

  36. Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, krogstad AL, Larsen FG, Iglesias L, Buckley C, Bibby AJ. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82:131-5.

  37. Guenther L, Cambazard F, Van de Kerkhof PCM, Snellman E, Kragballe K, Chu AC, Tegner E, García-Díez A, Springborg J. Efficacy and safety of a new combination of caocipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: A randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147:316-23.

  38. Kaufmann R, Viví AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, Douglas WS, Lowson D, Mascaró JM, Murphy GM, Stymne B. A new calcipotriol/betamethasone dipropionate formulation (Daivober™) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205:389-93.

  39. Kragballe K, Fogh K, Sogaard H. Long-term efficacy and tolerability of topical calcipotriol in psoriasis. Acta Derm Venereol 1991;71:475-8.

  40. Ramsay CA, Berth-Jones J, Brundin G. Cunliffe WJ, Dubertret L, Van de Kerkhof PCM, Menne T, Wegman E. Use of long-term calcipotriene in chronic plaque psoriasis. Dermatology 1994;189:260-4.

  41. Ellis JP, Griffiths WAD, Klaber MR. Long- term treatment ofchronic plaque psoriasis with calcipotriol ointment in patients unresponsive to short- contact dithranol. Eur J of Clinical Research 1995; 7:247-57.

  42. Cullen S. Long-term effectiveness and safety of topical calcipotriene for psoriasis. Soth Med J 1996; 89: 1053-6.

  43. Guenther L. Cambazard F, Kerkhof PCM van de, Snellman E, Kragball K, Chu AC, Tegner E, Garcia-Diez A, Sprinborg J. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treament of psoriasis vulgaris: a randomised, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147: 316-23.

  44. Papp KA. Early onset of action an efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48:48-54.

  45. Koo J. How and why to use sequential therapy of psoriasis. Skin Aging 1998; 6:42-6.

  46. Koo JY. Current consensus and update on psoriasis therapy: a prespective from the US. J Dermatol 1999; 26:723-33.

  47. Lebwohl M, Yoles A, Lombardi K, Lou W. Calcipotriene ointment and halobetasol ointment in the long-term of psoriasis: Effects on the duration of improvement. J Am Acad Dermatol 1998; 39:447:50.

  48. Kragballe K, Noerrelund KL. A highly effective once-daily treatment with a new calcipotriol / betamethasone ointment in psoriasis vulgaris. Br J Dermatol 2002; 147: 1073-4.




2020     |     www.medigraphic.com